Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding

Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding
复制标题

DOI:
10.1002/jps.21317
复制
发表时间:
2008-10-01
影响因子:
3.8
通讯作者:
Sohal, Bindi
Sohal, Bindi
中科院分区:
医学3区
文献类型:
--
作者:
Waters, Nigel J.;Jones, Rachel;Sohal, Bindi

文献摘要

被引文献

相似文献

平衡透析(艾德)是研究药物结合的最常用方法之一,其中主要缺点是达到平衡的时间(在6和24小时之间变化)、长的测定制备时间和自动化的复杂性。快速平衡透析(RED)装置最近已上市(Pierce Biotechnology,ThermoFisher Scientific,Waltham,MA),可减少制备和平衡时间。RED装置包括一个Teflon基板,可容纳多达48个一次性透析池。每个透析插件由两个并排的腔室组成,腔室由具有高膜表面积与体积比的透析膜的垂直圆柱体分隔。作为与标准品艾德的比较分析,对测量人血浆蛋白结合率(PPB)的RED方法进行了独立验证,以评价平衡时间、试验重现性和准确度以及易用性。使用涵盖一系列理化性质的多种IS市售药物,我们已证明这是一种稳健且准确的方法,具有较短的制备和透析时间,能够自动化作为PPB测定的高通量测定。(C)2008威利利斯公司
Equilibrium dialysis (ED) is one of the most frequently used approaches to investigate drug binding, where the major drawbacks are the time to reach equilibrium (varying between 6 and 24 h), a long assay preparation time and complexity of automation. A rapid equilibrium dialysis (RED) device has recently become commercially available (Pierce Biotechnology, ThermoFisher Scientific, Waltham, MA) offering the potential for reduced preparation and equilibration times. The RED device comprises a Teflon base plate which holds up to 48 disposable dialysis cells. Each dialysis insert is made up of two side-by-side chambers separated by a vertical cylinder of dialysis membrane with a high membrane surface area-to-volume ratio. An independent validation of the RED approach for the measurement of human plasma protein binding (PPB) was carried out as a comparative analysis with standard ED evaluating equilibration time, assay reproducibility and accuracy and ease of use. Using a diverse set of IS commercially available drugs spanning a range of physicochemical properties we have shown this to be a robust and accurate methodology, with a shorter preparation and dialysis time, capable of being automated as a high-throughput assay for the determination of PPB. (C) 2008 Wiley-Liss, Inc.